Company profile
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, operates globally as a biopharmaceutical company focused on discovering, developing, manufacturing, and delivering human therapeutics. The firm concentrates its research and development efforts on critical therapeutic areas such as inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Its extensive product portfolio includes a range of impactful medicines. Examples feature Enbrel for autoimmune conditions like psoriasis and arthritis, Neulasta to mitigate infection risk in cancer patients with low white blood cell counts, Prolia for postmenopausal osteoporosis, and Repatha to decrease the likelihood of heart attack, stroke, and coronary revascularization. Other key offerings include Xgeva, Otezla, Aranesp, and KYPROLIS, among numerous additional treatments like Nplate, Vectibix, and Aimovig. Amgen distributes its products through pharmaceutical wholesalers and direct-to-consumer channels, serving a wide array of healthcare providers, including physicians, clinics, hospitals, and pharmacies. The company actively pursues strategic collaborations to advance its pipeline. Notable partnerships include an agreement with Verastem, Inc., among others, to investigate VS-6766 in combination with lumakrastm (Sotorasib) for KRAS G12C-mutant non-small cell lung cancer. It also works with Kyowa Kirin Co., Ltd. to develop KHK4083 for atopic dermatitis and other autoimmune diseases, and engages in research alliances with Neumora Therapeutics, Inc. and Plexium, Inc.
- CEO
- Robert A. Bradway
- Employees
- 31,500
- IPO date
- 03 Jan 2000
- ISIN
- US0311621009
